NVSEF - Novartis AG

Other OTC - Other OTC Delayed Price. Currency in USD
85.09
-0.50 (-0.58%)
At close: 11:29AM EDT
Stock chart is not supported by your current browser
Previous Close85.59
Open0.00
Bid0.00 x 0
Ask0.00 x 0
Day's Range0.00 - 0.00
52 Week Range
Volume0
Avg. Volume31,537
Market Cap199.78B
Beta0.83
PE Ratio (TTM)31.07
EPS (TTM)2.74
Earnings DateN/A
Forward Dividend & Yield2.73 (3.19%)
Ex-Dividend Date2017-03-02
1y Target EstN/A
Trade prices are not sourced from all markets
  • Gilead shares up after FDA approves breakthrough cancer treatment
    Yahoo Finance Video4 days ago

    Gilead shares up after FDA approves breakthrough cancer treatment

    The FDA has approved a new cancer treatment developed by Gilead's $11B acquisition Kite Pharma. Yahoo Finance’s Alexis Christoforous, Rick Newman, and Nicole Sinclair have more.

  • FDA approves Gilead's cancer drug
    CNBC Videos4 days ago

    FDA approves Gilead's cancer drug

    CNBC's Meg Tirrell shares details of the FDA'a approval of Gilead's new immunotherapy drug to treat patients with non-Hodgkin lymphoma.

  • Training cells to fight cancer
    CNBC Videos24 days ago

    Training cells to fight cancer

    In today’s Modern Medicine series, CNBC’s Meg Tirrell brings us the story of a little girl whose life was saved by a different kind of cancer treatment.

  • Historic treatment, historic price
    CNBC Videos24 days ago

    Historic treatment, historic price

    Novartis raised eyebrows with the price of its newly approved CAR-T therapy: $475,000. But some argue the price makes sense, given that CAR-T is a one-time treatment, not a chronic therapy, and there are only about 600 patients each year who may take i...

  • Gilead Slaps Mega-Price on Its Newly Approved CAR-T
    Motley Fool3 days ago

    Gilead Slaps Mega-Price on Its Newly Approved CAR-T

    Gilead Sciences' premium price for Yescarta could help offset hep C headwinds.

  • TheStreet.com4 days ago

    FDA Approves Gene Therapy to Treat Large B-Cell Lymphoma

    Gilead Sciences' Kite will make a futuristic one-time dose that claims to cure a rare blood cancer in a few weeks. It costs about a third of a million dollars.

  • American City Business Journals4 days ago

    Drugmaker Novartis to close 450-employee Sandoz plant in Broomfield

    Swiss drugmaker Novartis AG plans to reduce or drop production of some generic drugs and will close its 450-employee Sandoz plant in Broomfield over the next two years as a result. The Sandoz facility has been in Broomfield for 42 years. Novartis (NVS) plans to consolidate production of drug ingredients at a sister plant in Wilson, North Carolina, and shut down the Broomfield manufacturing plant by the end of 2019, the company said.

  • Novartis Reports Positive Results on Thrombocytopenia Drug
    Zacks4 days ago

    Novartis Reports Positive Results on Thrombocytopenia Drug

    Novartis AG (NVS) announced encouraging results on Revolade from the EXTEND study.

  • Reuters4 days ago

    Novartis to shut U.S. generics plant, cut 450 jobs

    Swiss drugmaker Novartis is to cut 450 jobs in the United States over the next two years as it gradually shuts a generics manufacturing plant in Colorado and discontinues some products in the face of intense price pressures. "To remain competitive in the U.S., Novartis will discontinue or divest limited growth products in saturated markets," a company spokesman said on Thursday. The shutdown of Novartis's Sandoz division plant in the Denver suburb of Broomfield was originally reported by the Denver Post.

  • The Wall Street Journal4 days ago

    Gilead Gets FDA Approval for New Cancer Therapy

    Gilead Sciences’ $11 billion bet on Kite Pharma is poised to pay off, with the approval of Kite’s flagship cell-therapy treatment for advanced lymphoma patients.

  • Reuters4 days ago

    U.S. FDA approves Gilead cancer gene therapy; price set at $373,000

    U.S. regulators approved on Wednesday a new therapy for a type of lymphoma, which was developed by Gilead Science Inc's Kite Pharma, marking the second approval for this potentially revolutionary approach to fighting cancer. The Food and Drug Administration approved the gene therapy, to be sold under the name Yescarta, to treat adults with large B-cell lymphoma, a type of non-Hodgkin lymphoma, who have failed to respond to other treatments.

  • Forbes4 days ago

    FDA Approves Another Amazing And Costly Cancer-Killing Gene Therapy

    The Food and Drug Administration just approved Yescarta, a treatment that genetically modifies a patient's own white cells to battle lymphoma. The price? $373,000.

  • What's in the Cards for Novartis (NVS) This Earnings Season?
    Zacks5 days ago

    What's in the Cards for Novartis (NVS) This Earnings Season?

    Swiss pharmaceutical company Novartis AG (NVS) is scheduled to report third-quarter 2017 results on Oct 24.

  • Market Realist5 days ago

    Inside Novartis’s Performance in 3Q17

    NVS stock rose ~2.8% in 3Q17 and has risen 18.7% YTD (year-to-date) as of October 16.

  • Innovative Pipelines & Regulatory Catalysts to Drive Pharma Stocks
    Zacks6 days ago

    Innovative Pipelines & Regulatory Catalysts to Drive Pharma Stocks

    Innovative Pipelines & Regulatory Catalysts to Drive Pharma Stocks

  • Let's Talk About CAR-T
    GuruFocus.com7 days ago

    Let's Talk About CAR-T

    A quick overview of treatment and the major players in bringing promising cancer-fighting technologies to market

  • Reuters12 days ago

    Novartis decides not to sell Roche stake chairman tells newspaper

    Novartis (NOVN.S) has decided not to sell its roughly $14 billion (10.61 billion pounds), 33 percent voting stake in Roche (ROG.S) following a review, Chairman Joerg Reinhardt said in an interview published on Wednesday in Swiss newspaper HandelsZeitung. "We said we would review whether it makes sense to sell the stake," Reinhardt told the newspaper. In May 2016, Chief Executive Officer Joe Jimenez said he was ready to sell the Roche stake without demanding a premium and that Novartis has been discussing options with banks.

  • Forbes12 days ago

    Here Come More Gene Therapies -- And More Pricing Debates

    Gene therapies like Spark Therapeutics' upcoming Luxturna and Novartis' FDA-approved Kymriah are raising concerns about the rising cost of health care, leading some experts to suggest new ways to price treatments based on the benefits they offer.

  • 4 Large-Cap Drug Stocks to Buy on Solid Momentum Ahead of Q3
    Zacks18 days ago

    4 Large-Cap Drug Stocks to Buy on Solid Momentum Ahead of Q3

    The Large Cap Pharmaceuticals industry has gained 20.7% year to date, outpacing 14.7% gain for the S&P 500.

  • Barrons.com21 days ago

    [$$] Lilly Faces Off With Pfizer, Novartis

    Credit Suisse Lilly’s Verzenio (abemaciclib) has obtained Food and Drug Administration approval for use in patients with HR+, HER2- metastatic breast cancer who progressed on prior therapy. Given the data that we have seen for Lilly’s (LLY) product from the MONARCH-1 and MONARCH-2 studies, we had expected the approval, although it does comes three to four months earlier than we had expected, representing another example of the agency working to get innovative products to the market quickly. Along with approval for use in combination with fulvestrant, Verzenio has the unique indication (relative to key competitors Pfizer’s (PFE) Ibrance and Novartis’s (NVS) Kisqali) for use as monotherapy after endocrine therapy and chemotherapy in patients with metastatic disease.

  • CNBC24 days ago

    Two patients show the promise of a historic treatment, with an equally historic price tag

    Kymriah is among a new wave of therapies that use a patient's own cells as medicine. But this historic treatment comes with a historic price.

  • Forbes24 days ago

    Big Pharma Doesn't Want Health Outcomes To Sway Pricing -- At Least Not Yet

    Health insurers and pharmacy benefits managers argue that drug prices should be tied to the benefits the products bring to patients, but the pharma industry has been slow to buy into that model.

  • Novartis Could Acquire This Biotech — Why A Deal Is 'Very Logical'
    Investor's Business Daily25 days ago

    Novartis Could Acquire This Biotech — Why A Deal Is 'Very Logical'

    Advanced Accelerator Applications launched to a record high Thursday on rumors Novartis could attempt to take it over.

  • Why Advanced Accelerator Application SA Stock Jumped Higher Today
    Motley Fool25 days ago

    Why Advanced Accelerator Application SA Stock Jumped Higher Today

    An acquisition rumor has the radiopharmaceutical company's shares on the rise.

  • Reuters25 days ago

    Novartis forges UC Berkeley pact, sees drug hopefuls in 3 years

    Novartis's research head expects an alliance with a University of California chemistry lab to produce drug candidates within three years as the Swiss company accelerates its hunt for new medicines. Novartis announced the Novartis-Berkeley Center for Proteomics and Chemistry Technologies on Thursday. Basel-based Novartis hopes Berkeley scientists including Daniel Nomura, the professor who runs the lab, will speed its search for the Achilles' heels of hard-to-treat diseases.